Ceapro to Develop Enabling Pressurized Gas Expanded Technology (PGX) at Commercial and Demonstration Scale
EDMONTON, ALBERTA - 05/28/15 - Ceapro Inc. is a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, announced it will embark on a scale-up of its proprietary PGX technology to commercial and demonstration levels.
Gilles Gagnon, President and CEO of Ceapro, remarked, "The Company recently obtained the worldwide rights for PGX in all industrial applications and we believe PGX will drive significant value for Ceapro. We are committed to investing in the potential of the PGX platform. It is exciting to see how this enabling technology has evolved from an in-house beta glucan project to a global technology platform with many unique potential applications."